Avoid Using Volatile Markers on GMP Documents to Maintain Integrity
Remember: GMP documentation must be indelible, permanent, and traceable—using volatile or erasable markers compromises data integrity and violates regulatory expectations.
Why This Matters in GMP
Good documentation practices (GDP) are foundational to GMP compliance. All entries in controlled documents—such as batch manufacturing records, logbooks, calibration reports, and deviation forms—must be made in ink that is permanent, legible, and resistant to alteration. Volatile markers (like erasable pens or alcohol-based ink that fades over time) pose a serious risk to data integrity because they can be erased, overwritten, or degrade with time or environmental exposure. In regulated environments, such changes can go undetected, leading to inaccurate records, falsified data, and loss of batch traceability.
Regulators view documentation not just as evidence of work done, but as legal records of GMP compliance. Use of inappropriate writing tools undermines the credibility of records and can result in critical observations during audits. It also impacts internal traceability, error investigation, and document retention over the product’s lifecycle.
Regulatory and Compliance Implications
FDA 21 CFR Part 211.180 and 211.194 require complete, accurate, and permanent documentation of GMP records. EU GMP
Implementation Best Practices
- Mandate the use of indelible, permanent blue or black ballpoint pens for all GMP entries.
- Explicitly prohibit the use of pencils, gel pens, erasable markers, or white-out in SOPs and training programs.
- Train personnel in GDP and conduct routine checks of logbooks and records for compliance with ink usage standards.
- Control the distribution of writing instruments in GMP areas through QA oversight or tool kits.
- In case of accidental use, cross out incorrect entries with a single line, record reason, initials, and date per GDP principles.
Regulatory References
- FDA 21 CFR Part 211.180 – Record Maintenance and Accessibility
- FDA 21 CFR Part 211.194 – Laboratory Records and Integrity
- EU GMP Chapter 4 – Documentation Requirements
- WHO GMP / Schedule M – Data Integrity and Document Control